{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:07:42Z","timestamp":1783127262991,"version":"3.54.6"},"reference-count":74,"publisher":"Informa UK Limited","issue":"13","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Substance Use &amp; Misuse"],"published-print":{"date-parts":[[2023,11,10]]},"DOI":"10.1080\/10826084.2023.2247071","type":"journal-article","created":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T12:13:30Z","timestamp":1692188010000},"page":"1751-1760","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Re-Purposing FDA-Approved Drugs for Opioid Use Disorder"],"prefix":"10.1080","volume":"58","author":[{"given":"Krishna","family":"Patel","sequence":"first","affiliation":[{"name":"Doctor of Medicine Program, Penn State College of Medicine, Hershey, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Waldron","sequence":"additional","affiliation":[{"name":"Doctor of Medicine Program, Penn State College of Medicine, Hershey, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Graziane","sequence":"additional","affiliation":[{"name":"Departments of Anesthesiology and Perioperative Medicine and Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,8,16]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000287"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12395"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/10826080500294924"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.12445"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0502"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0220-x"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.12802"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.686845"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.627229"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12205"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.8369.1"},{"key":"e_1_3_4_13_1","unstructured":"US FDA. (2018). CIII highlights of prescribing information these highlights do not include all the information needed to use SUBUTEX \u00ae safely and effectively. See full prescribing information for SUBUTEX. SUBUTEX (Buprenorphine Sublingual Tablets) for sublingual administration. Indivior Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/020732s018lbl.pdf."},{"key":"e_1_3_4_14_1","unstructured":"US FDA. (2019). BUPRENEX \u00ae (Buprenorphine Hydrochloride)."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2011.01628.x"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmip.2020.100059"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199802000-00009"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.157.11.1835"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2008.07.012"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-200106000-00006"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2018.2143"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-007-1020-8"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070112"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12333"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3109\/08039489309104119"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200262002-00002"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.12.030"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/19371918.2013.774673"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2011.09.010"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.6.617"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(15)00366-1"},{"issue":"4","key":"e_1_3_4_32_1","first-page":"CD002980","article-title":"Acyclovir for treating varicella in otherwise healthy children and adolescents","volume":"2005","author":"Klassen T. P.","year":"2001","unstructured":"Klassen, T. P., Belseck, E. M., Wiebe, N., & Hartling, L. (2001). Acyclovir for treating varicella in otherwise healthy children and adolescents. Cochrane Database of Systematic Reviews, 2005(4):CD002980.","journal-title":"Cochrane Database of Systematic Reviews,"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2009.07.018"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2019.05.023"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.09.008"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2008.0094"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12862"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/1744806920912931"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2022.117"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2009.00983.x"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2017.10.012"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.07.001"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.15288\/jsad.2012.73.820"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0000000000000510"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v69n0808"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1037\/\/0022-006x.64.4.677"},{"issue":"19","key":"e_1_3_4_48_1","first-page":"315","article-title":"Update of naltrexone treatment","author":"O\u2019Brien C. P.","year":"1978","unstructured":"O\u2019Brien, C. P., Greenstein, R., & Woody, G. E. (1978). Update of naltrexone treatment. NIDA Research Monograph, (19), 315\u2013320.","journal-title":"NIDA Research Monograph"},{"key":"e_1_3_4_49_1","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell J. K. Gladden R. M. & Seth P. (2017). Trends in deaths involving heroin and synthetic opioids excluding methadone and law enforcement drug product reports by Census Region\u2014United States 2006\u20132015.\" In Morbidity and Mortality Weekly Report. U.S. Department of Health and Human Services: Center for Disease Control and Prevention.","DOI":"10.15585\/mmwr.mm6634a2"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1970.04000040057011"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1179\/1573658X15Y.0000000004"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2011.06.008"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina57111256"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1976.01770080111011"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6450a3"},{"key":"e_1_3_4_56_1","unstructured":"SAMHSA. (2023). Co-occurring disorders and other health conditions SAMSHSA.gov.  https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/medications-counseling-related-conditions\/co-occurring-disorders"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e318287019c"},{"key":"e_1_3_4_58_1","volume-title":"Handbook of Evidence-Based Prevention of Behavioral Disorders in Integrated Care: A Stepped Care Approach","author":"Schainker L. M.","year":"2021","unstructured":"Schainker, L. M., Voss, M. W., & Yaugher, A. C. (2021). Integrated care approach to the prevention of opioid use disorder. In W. O\u2019Donohue and M. Zimmermann (Eds.), Handbook of Evidence-Based Prevention of Behavioral Disorders in Integrated Care: A Stepped Care Approach Springer International Publishing."},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.2975\/35.3.2012.235.243"},{"key":"e_1_3_4_60_1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1358\/mf.2005.27.5.908643","article-title":"Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes","volume":"27","author":"Silvestre J. S.","year":"2005","unstructured":"Silvestre, J. S., & Prous, J. (2005). Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol, 27, 289\u2013304.","journal-title":"Methods Find Exp Clin Pharmacol,"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-011-2263-y"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1037\/h0034534"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2010.01270.x"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109054"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1286-4579(02)01645-3"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2016.1100960"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.17080913"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2020214"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.08.027"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-003-1504-0"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-1809.1955.tb01348.x"},{"key":"e_1_3_4_72_1","volume-title":"Adherence to long-term therapies: Evidence for action","author":"World Health Organization","year":"2003","unstructured":"World Health Organization. (2003). Adherence to long-term therapies: Evidence for action. World Health Organization."},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-1600.2012.00443.x"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2019.112585"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-01011-y"}],"container-title":["Substance Use &amp; Misuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10826084.2023.2247071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T19:31:13Z","timestamp":1695843073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10826084.2023.2247071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,16]]},"references-count":74,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,11,10]]}},"alternative-id":["10.1080\/10826084.2023.2247071"],"URL":"https:\/\/doi.org\/10.1080\/10826084.2023.2247071","relation":{},"ISSN":["1082-6084","1532-2491"],"issn-type":[{"value":"1082-6084","type":"print"},{"value":"1532-2491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=isum20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=isum20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-08-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}